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Abstract
The voltage-gated sodium channel NaV1.7 plays a critical role in
pain pathways. We generated an epitope-tagged NaV1.7 mouse
that showed normal pain behaviours to identify channel-inter-
acting proteins. Analysis of NaV1.7 complexes affinity-purified
under native conditions by mass spectrometry revealed 267
proteins associated with Nav1.7 in vivo. The sodium channel b3
(Scn3b), rather than the b1 subunit, complexes with Nav1.7, and
we demonstrate an interaction between collapsing-response medi-
ator protein (Crmp2) and Nav1.7, through which the analgesic drug
lacosamide regulates Nav1.7 current density. Novel NaV1.7 protein
interactors including membrane-trafficking protein synaptotag-
min-2 (Syt2), L-type amino acid transporter 1 (Lat1) and trans-
membrane P24-trafficking protein 10 (Tmed10) together with
Scn3b and Crmp2 were validated by co-immunoprecipitation (Co-
IP) from sensory neuron extract. Nav1.7, known to regulate opioid
receptor efficacy, interacts with the G protein-regulated inducer of
neurite outgrowth (Gprin1), an opioid receptor-binding protein,
demonstrating a physical and functional link between Nav1.7 and
opioid signalling. Further information on physiological interactions
provided with this normal epitope-tagged mouse should provide
useful insights into the many functions now associated with the
NaV1.7 channel.
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Introduction
Pain is a major clinical problem. A 2012 National Health Interview
Survey (NHIS) in the United States revealed that 25.3 million adults
(11.2%) suffered from daily (chronic) pain and 23.4 million
(10.3%) reported severe pain within a previous 3-month period
(Nahin, 2015). Many types of chronic pain are difficult to treat as
most available drugs have limited efficacy and can cause side
effects. There is thus a huge unmet need for novel analgesics
(Woodcock, 2009). Recent human and animal genetic studies have
indicated that the voltage-gated sodium channel (VGSC) NaV1.7
plays a crucial role in pain signalling (Nassar et al, 2004; Cox et al,
2006; Dib-Hajj et al, 2013), highlighting NaV1.7 as a promising drug
target for development of novel analgesics (Habib et al, 2015;
Emery et al, 2016).
VGSCs consist of a large pore-forming a-subunit (~260 kDa)
together with associated auxiliary b-subunits (33–36 kDa) and play
a fundamental role in the initiation and propagation of action poten-
tials in electrically excitable cells. Nine isoforms of a-subunits
(NaV1.1–1.9) that display distinct expression patterns, and variable
channel properties have been identified in mammals (Frank &
Catterall, 2003). NaV1.7, encoded by the gene SCN9A in humans, is
selectively expressed peripherally in dorsal root ganglion (DRG),
trigeminal ganglia and sympathetic neurons (Toledo-Aral et al,
1997; Black et al, 2012), as well as in the central nervous system
(Weiss et al, 2011; Branco et al, 2016). As a large membrane ion
channel, NaV1.7 produces a fast-activating, fast-inactivating and
slowly repriming current (Klugbauer et al, 1995), acting as a thres-
hold channel to contribute to the generation and propagation of
action potentials by amplifying small sub-threshold depolarisations
(Rush et al, 2007). The particular electrophysiological characteris-
tics of NaV1.7 suggest that it plays a key role in initiating action
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potentials in response to depolarisation of sensory neurons by
noxious stimuli (Habib et al, 2015). In animal studies, our previous
results demonstrated that conditional NaV1.7 knockout mice have
major deficits in acute, inflammatory and neuropathic pain (Nassar
et al, 2004; Minett et al, 2012). Human genetic studies show that
loss-of-function mutations in NaV1.7 lead to congenital insensitivity
to pain, whereas gain-of-function mutations cause a range of painful
inherited disorders (Cox et al, 2006; Dib-Hajj et al, 2013). Recent
studies also show that NaV1.7 is involved in neurotransmitter
release in both the olfactory bulb and spinal cord (Weiss et al, 2011;
Minett et al, 2012). Patients with recessive NaV1.7 mutations are
normal (apart from being pain-free and anosmic), suggesting that
selective NaV1.7-blocking drugs are therefore likely to be effective
analgesics with limited side effects (Cox et al, 2006).
Over the past decade, an enormous effort has been made to
develop selective NaV1.7 blockers. Efficient and selective NaV1.7
antagonists have been developed; however, NaV1.7 antagonists
require co-administration of opioids to be fully analgesic (Minett et al,
2015). NaV1.7 thus remains an important analgesic drug target and an
alternative strategy to target NaV1.7 could be to interfere with either
intracellular trafficking of the channel to the plasma membrane, or the
downstream effects of the channel on opioid peptide expression.
Although some molecules, such as Crmp2, ubiquitin ligase Nedd4-2,
fibroblast growth factor 13 (FGF13) and PDZ domain-containing
protein Pdzd2, have been reported to associate with the regulation of
trafficking and degradation of NaV1.7, the entire protein–protein inter-
action network of NaV1.7 still needs to be defined (Shao et al, 2009;
Dustrude et al, 2013; Laedermann et al, 2013; Bao, 2015; Yang et al,
2017). Affinity purification (AP) and targeted tandem affinity purifica-
tion (TAP) combined with mass spectrometry (MS) is a useful method
for mapping the organisation of multiprotein complexes (Angrand
et al, 2006; Wildburger et al, 2015). Using the AP-MS or TAP-MS
method to characterise protein complexes from transgenic mice allows
the identification of complexes in their native physiological environ-
ment in contact with proteins that might only be specifically expressed
in certain tissues (Fernandez et al, 2009). The principal aim of this
study was to identify new protein interaction partners and networks
involved in the trafficking and regulation of the sodium channel
NaV1.7 using mass spectrometry and our recently generated epitope
(TAP)-tagged NaV1.7 knock-in mouse. Such information should throw
new light on the mechanisms through which NaV1.7 regulates a vari-
ety of physiological systems, as well as propagating action potentials,
especially in pain signalling pathways.
Results
The TAP-tag does not affect NaV1.7 channel function
Prior to generating the TAP-tagged NaV1.7 knock-in mouse, we
tested the channel function of TAP-tagged NaV1.7 in HEK293 cells
by establishing a HEK293 cell line stably expressing TAP-tagged
NaV1.7. A 5-kDa TAP-tag consisting of a poly-histidine affinity tag
(HAT) and a 3x FLAG-tag in tandem (Terpe, 2003), separated by a
unique TEV protease cleavage site, was fused to the C-terminus of
NaV1.7 (Fig 1A). The expression of TAP-tagged NaV1.7 was detected
with immunocytochemistry using an anti-FLAG antibody. The result
showed that all the HEK293 cells expressed TAP-tagged NaV1.7
(Fig 1B). The channel function of TAP-tagged NaV1.7 was examined
with electrophysiological analysis, and the result showed that all the
cells presented normal functional NaV1.7 currents (Fig 1C). Activa-
tion and fast inactivation data were identical for wild-type NaV1.7
and TAP-tagged NaV1.7 (Fig 1D) demonstrating that the TAP-tag
does not affect the channel function of NaV1.7.
Generation of a TAP-tagged NaV1.7 mouse
We used a conventional gene targeting approach to generate an
epitope-tagged NaV1.7 mouse. The gene targeting vector was
constructed using an Escherichia coli recombineering-based method
(Bence et al, 2005; Fig EV1). A TAP-tag, which contains a HAT
domain, a TEV cleavage site and 3x FLAG-tags (Fig 1A), was
inserted into the open reading frame at the 30-end prior to the stop
codon in exon 27 of NaV1.7 (NCBI Reference: NM_001290675;
Fig 2A). The final targeting vector construct containing a 50 homol-
ogy arm (3.4 kb), a TAP-tag, neomycin cassette and a 30 homology
arm (5.8 kb; Fig 2B) was transfected into the 129/Sv embryonic
stem (ES) cells. Twelve colonies with the expected integration (tar-
geting efficiency was 3.5%) were detected by Southern blot analyses
(Fig 2C). Germline transmission and intact TAP-tag insertion after
removal of the neomycin (neo) cassette were confirmed with South-
ern blot, PCR and RT–PCR, respectively (Fig 2D–F). This mouse line
is henceforth referred to as NaV1.7
TAP.
NaV1.7
TAP mice have normal pain behaviour
The homozygous NaV1.7
TAP knock-in mice (KI) were healthy,
fertile and apparently normal. Motor function of the mice was
examined with the Rotarod test. The average time that KI animals
stayed on the rod was similar to the WT mice (Fig 3A), suggest-
ing there is no deficit on motor function in the KI mice. The
animal responses to low-threshold mechanical, acute noxious
thermal, noxious mechanical stimuli and acute peripheral
inflammation were examined with von Frey filaments, Harg-
reaves’ test, Randall–Selitto apparatus and formalin test, respec-
tively. The results showed that TAP-tagged KI mice had identical
responses to these stimuli compared to the littermate WT control
mice (Fig 3B–E), indicating NaV1.7
TAP mice have normal acute
pain behaviour.
Expression pattern of TAP-tagged NaV1.7 in the nervous system
We used immunohistochemistry to examine the expression pattern
of TAP-tagged NaV1.7 in the nervous system of NaV1.7
TAP mice. The
results showed that the FLAG-tag was expressed in the olfactory
bulb, with strong staining visible in the olfactory nerve layer, the
glomerular layer, and in the accessory olfactory bulbs (Fig 4A–D),
consistent with previous results (Weiss et al, 2011). In the brain,
FLAG-tag expression was present in the medial habenula, the
anterodorsal thalamic nucleus, the laterodorsal thalamic nucleus
and in the subfornical organ that is located in the roof of the dorsal
third ventricle (Fig 4E and F) and is involved in the control of thirst
(Oka et al, 2015). The FLAG-tag was also present in neurons of the
posterodorsal aspect of the medial amygdala and in the hypothala-
mus in neurons of the arcuate nucleus (Fig 4G–I) as confirmed in a
recent study (Branco et al, 2016). A clear staining appeared in
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Figure 1. Characterisation of TAP-tagged NaV1.7 in HEK293 cells.
A The diagram of TAP-tagged SCN9A cDNA construct used to establish the stably expressing TAP-tagged NaV1.7 HEK293 cell line. A sequence encoding a TAP-tag was
cloned immediately upstream of the stop codon of SCN9A coding the wild-type NaV1.7.
B Left panel: Representative immunohistochemistry with an anti-FLAG antibody (in green) on HEK293 cells stably expressing TAP-tagged NaV1.7 (top panel) and parental
HEK293 cells (bottom panel). Middle panel: Cell nuclei were costained with DAPI (blue). Right panel: the left panels were merged to the middle panels. Scale bar = 25 lm.
C Representative current traces recorded from HEK293 cells stably expressing either the wild-type NaV1.7 or the TAP-tagged NaV1.7 in response to depolarisation steps
from 100 to 40 mV.
D Left panel: I(V) curves obtained in Nav1.7- and TAP-tagged NaV1.7-expressing cells using the same protocol as in (C), showing no significant difference in voltage of
half-maximal activation (V1/2; 9.54  1.08 mV for NaV1.7, n = 10; and 8.12  1.07 mV for TAP-tagged NaV1.7, n = 14; P = 0.3765, Student’s t-test) and reversal
potential (Vrev; 61.73  3.35 mV for NaV1.7, n = 10; and 8.12  1.07 mV for TAP-tagged NaV1.7, n = 14; P = 0.9114, Student’s t-test). Right panel: Voltage
dependence of fast inactivation, assessed by submitting the cells to a 500-ms prepulse from 130 to 10 mV prior to depolarisation at 10 mV. No significant
difference in the voltage of half inactivation was observed between the two cell lines (V1/2 of 64.58  1.32 mV for NaV1.7, n = 10; and 64.39  1.06 for TAP-
tagged NaV1.7, n = 14; P = 0.9100, Student’s t-test). All data are mean  SEM.
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Figure 2. Generation of TAP-tagged NaV1.7 knock-in mice.
A The location of TAP-tag in the NaV1.7 locus. A sequence encoding a TAP-tag peptide comprised of a HAT domain, TEV cleavage site and 3 FLAG-tags was inserted
immediately prior to the stop codon (indicated as a star) at the extreme C-terminus of NaV1.7.
B Schematic diagrams of the targeting strategy. Grey boxes represent NaV1.7 exons (exon numbers are indicated on the box), black box represents TAP-tag, thick black lines
represent homologous arms, and the small triangle box represents the single LoxP site, respectively. The positions of the external probes used for Southern blotting are
indicated in the diagram. Neomycin (neo), DTA expression cassettes and restriction enzyme sites and expected fragment sizes for Southern blotting are also indicated.
C Southern blot analysis of genomic DNA from Founder 1 mice (TAP-tagged NaV1.7 carrying the neo cassette). Genomic DNA was digested with StuI and was then
hybridised with either 50 or 30 external probe. Wild-type (WT) allele was detected as a 13.8 kb fragment using either 50 or 30 probes. Knock-in allele (KI) was detected
as either a 6.6-kb (50 probe) or a 7.3-kb (30 probe) fragment.
D Southern blot analysis of TAP-tagged NaV1.7 allele after Cre recombination. Genomic DNA was digested either with BspHI or PsiI and was then hybridised with either
50 (BspHI) or 30 (PsiI) external probe. WT alleles were detected as 5.8 kb (50 probe) and 8.4 kb (30 probe) fragments, respectively. The neo-deleted TAP-tagged NaV1.7
alleles were detected as 4.5-kb (50 probe) and 6.1-kb (30 probe) fragments, respectively.
E Genotyping analysis by PCR. Representative result of the PCR screening of NaV1.7
TAP mice showing the 411-bp band (KI allele) and the 170-bp band (WT allele). The
location of primers used for PCR is indicated with black arrows.
F TAP-tagged NaV1.7 expression analysis with RT–PCR. Total RNA was isolated from DRG of NaV1.7
TAP mice, and cDNA synthesis was primed using oligo-dT. PCR was
performed with the primers indicated with black arrows. A 1.5-kb WT band and a 1.8-kb KI band were detected from either littermate WT control animals or
NaV1.7
TAP KI mice, respectively.
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neurons of the substantia nigra reticular region and the red nucleus
magnocellular region of the midbrain, and in neurons of the pontine
nuclei located in the hindbrain (Fig 4J–L). In the spinal cord, FLAG-
tag expression was visible in the superficial layer of the dorsal horn.
Costaining of the spinal cord with isolectin B4 (IB4), a marker for
the inner part of lamina II, showed that the TAP-tagged NaV1.7 was
expressed in laminae I, II and III (Fig 4M–O). In the PNS, however,
there was no positive FLAG-tag staining found in DRG, sciatic nerve
or skin nerve terminals (data not shown). This could be because of
masking of the tag in the PNS, preventing the antibody binding. We
also examined the TAP-tagged NaV1.7 expression pattern in
different tissues with Western blot using an anti-HAT antibody.
TAP-tagged NaV1.7 bands were present in olfactory bulb, hypothala-
mus, spinal cord, sciatic nerve and DRG, but not detectable in
cortex, cerebellum, skin, lung, heart and pancreas (Fig 5E).
Optimisation of single-step- and tandem affinity purification of
TAP-tagged NaV1.7
The TAP-tag on NaV1.7 offered the possibility of two consecutive
affinity purifications, a single-step affinity purification (ss-AP; steps
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Figure 3. Pain behaviour tests.
A Rotarod test showed no motor deficits in TAP-tagged NaV1.7 animals (n = 7, WT; n = 7, KI; P = 0.8619, Student’s t-test).
B Responses to low-threshold mechanical stimulation by von Frey filaments were normal in the KI mice (P = 0.9237, Student’s t-test).
C Hargreaves’ apparatus demonstrated identical latencies of response to thermal stimulation (n = 7, WT; n = 7, KI; P = 0.3038, Student’s t-test).
D Acute mechanical pressure applied with the Randall–Selitto apparatus demonstrated identical behaviour in KI and WT mice (n = 7, WT; n = 7, KI; P = 0.7124, Student’s t-test).
E Formalin test. Licking/biting response to acute peripheral inflammation induced by intraplantar injection of 5% formalin in hind-paw was recorded. Left panel, the
time course of development of the response of KI mice (black squares) and WT littermate controls (white squares) showed similar response patterns (n = 10, WT;
n = 7, KI; P = 0.2226, two-way ANOVA). Right panel, the early (0–10 min) and late (10–45 min) phases of the formalin response in KI and WT mice showed similar
responses (P = 0.1690, first phase; P = 0.5017, second phase; Student’s t-test) between KI and WT mice.
Data information: All data are mean  SEM.
▸Figure 4. Immunohistochemistry of FLAG-tag expression in the central nervous system (CNS).A–D In the main olfactory bulb (MOB) (A), FLAG-tag expression (in green) is visible in the olfactory nerve layer (ONL) and in the glomerular layer (GL) in TAP-tagged
NaV1.7 knock-in mice (KI) but not in the littermate wild-type controls (WT). The white square box in (A) is shown with high magnification in (B). In the posterior
olfactory bulb, staining is also evident in the (C) accessory olfactory bulb (AOB). Staining is absent in the (D) MOB and AOB of wild-type control mice.
E, F FLAG-tag expression is present (E) in the medial habenula (MHb, arrow), the anterodorsal thalamic nucleus (AD, arrow), the laterodorsal thalamic nucleus (LD,
dotted line) and (F) in the subfornical organ (SFO, arrow) located in the roof of the dorsal third ventricle.
G–I FLAG-tag expression is present (G) in neurons of (H) the posterodorsal aspect of the medial amygdala (MePD, arrow, dotted line) and in (I) the hypothalamus in
neurons of the arcuate nucleus (Arc, arrow, dotted line).
J–L FLAG-tag expression is present (J) in neurons of the substantia nigra reticular part (SNR) and (K) the red nucleus magnocellular part (RMC) of the midbrain, and (L)
in neurons of the pontine nuclei (Pn) located in the hindbrain.
M, N The cross section of lumbar spinal cord (L4) is labelled with anti-FLAG (in red). FLAG-tag expression is present in laminae I, II and III in spinal cord of KI mice (N)
but not in spinal cord of WT mice (M).
O The cross sections of spinal cord of KI mice were costained with laminae II marker IB4 (in green).
Data information: Sketches on the left illustrate the CNS regions and bregma levels (in mm) of the fluorescence images shown on the right. Scale bars: 500 lm (A, C, D,
G); 250 lm (E, J, K, M–O); 100 lm (B, F, I, L); 50 lm (H). cp, cerebral peduncle; CTX, cortex; DM, dorsomedial hypothalamic nucleus; EPL, external plexiform layer; ME,
median eminence; opt, optic tract; sm, stria medullaris; TH, thalamus; VMH, ventromedial hypothalamic nucleus; 3V, third ventricle.
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Fig 5A). CHAPS and DOC lysis buffers were evaluated to solubilise
TAP-tagged NaV1.7 and its protein complex from tissues, for exam-
ple DRG, spinal cord, olfactory bulbs and hypothalamus, in the co-
IP system. CHAPS is a non-denaturating zwitterionic detergent,
commonly used to extract membrane proteins in their native confor-
mation. In comparison with strong anionic detergents like SDS,
CHAPS preserves protein–protein interactions and is compatible
with downstream applications such as mass spectrometry. The
result showed that TAP-tagged NaV1.7 from DRG and olfactory
bulbs was clearly solubilised and precipitated by both purifications
—ss-AP and tandem affinity purification in 1% CHAPS buffer
(Fig 5B). Also, the result from ss-AP showed that TAP-tagged
NaV1.7 could be immunoprecipitated from hypothalamus, sciatic
nerve, spinal cord, olfactory bulb and DRG of KI mice, but not from
these tissues of WT control mice (Fig 5C). However, the DOC lysis
buffer, which was used to investigate the TAP-tagged PSD-95
protein complex (Fernandez et al, 2009), did not solubilise TAP-
tagged NaV1.7 from mouse tissue (data not shown).
Identification of TAP-tagged NaV1.7-associated complexes
by AP-MS
We next identified the components of NaV1.7 complexes using ss-
AP followed by Liquid chromatography–tandem mass spectrometry
(LC-MS/MS). Briefly, the TAP-tagged NaV1.7 complexes were
extracted from DRG, spinal cord, olfactory bulb and hypothalamus
using ss-AP (see Materials and Methods). In total, 189,606 acquired
spectra from 12 samples, in which each group (KI and WT) contains
six biological replicate samples and each sample was from one
mouse, were used for protein identification; 1,252 proteins were
identified with a calculated 0.96% false discovery rate (FDR); 267
proteins (Table EV1) met those criteria and were shortlisted
based on the criteria described in Materials and Methods. The
proteins only appearing in NaV1.7
TAP mice and the representatively
selected proteins are listed in Table 1. PANTHER cellular compo-
nent analysis of these 267 proteins revealed eight different cellular
components (Fig 6A). These proteins were further classified into 22
groups based on their function, including 12 membrane-trafficking
proteins, 23 enzyme modulators and four transcription factors
(Fig 6B).
Validation of TAP-tagged NaV1.7-interacting proteins using co-IP
The physical interactions between NaV1.7 and interacting protein
candidates were assessed using co-IP with DRG tissue extracts
from TAP-tagged NaV1.7 mice. A number of candidates of interest,
such as Scn3b, Syt2, Lat1, Tmed10, Gprin1, Crmp2, isoform 2 of
A-kinase anchor protein 12 (Akap12), neurofascin (Nfasc), neuro-
trimin (Ntm), kinesin-1 heavy chain (Kif5b), ankyrin-3 (Ank3) and
phosphatidylethanolamine-binding protein 1 (Pebp1), were chosen
from the NaV1.7-associated protein list previously identified by
MS (Table 1 and Table EV1). After ss-AP, the NaV1.7 complexes
were separated by SDS–PAGE and the protein interactors of
NaV1.7 were detected by Western blotting. Our results show that
all 12 candidates were detected by their specific antibodies
(Fig 5F).
We also validated six candidates (Scn3b, Syt2, Crmp2, Gprin1,
Lat1 and Tmed10) using co-IP in an in vitro system by co-expres-
sing the candidates in a TAP-tagged NaV1.7 stable cell line. The
mammalian expression vectors carrying cDNAs of these candi-
dates were transfected into a TAP-tagged NaV1.7 stable HEK293
cell line; 48 h of post-transfection, the proteins in the transfected
cells were extracted. The TAP-tagged NaV1.7 multiprotein
complexes were then immunoprecipitated with anti-FLAG anti-
body and analysed with Western blot using different specific anti-
bodies against those selected candidates. The Western blot
showed that all six candidates were detected with the expected
sizes on the blot (Fig 5D), confirming that these candidates are
contained in the NaV1.7 complex. In summary, all these potential
interacting proteins selected for further validation were confirmed
as interactors by co-IP, giving confidence in the Nav1.7TAP mass
spectrometry list.
▸Figure 5. Optimisation of single-step and tandem affinity purification, validation of identified protein–protein interactors and tissue expression pattern ofTAP-tagged NaV1.7 in NaV1.7TAP mice.
A Schematic illustrating the affinity purification (ss-AP and TAP) procedure using the tandem affinity tags separated with a TEV cleavage site.
B The proteins from DRG and olfactory bulbs were extracted in 1% CHAPS lysis buffer. After single-step and tandem affinity purification, TAP-tagged NaV1.7 was
detected using Western blotting with anti-HAT antibody.
C The proteins from different tissues including hypothalamus, sciatic nerve, spinal cord, olfactory bulbs and DRG from KI mice, and pooled tissues from WT mice were
extracted in 1% CHAPS lysis buffer. After single-step affinity purification, TAP-tagged NaV1.7 was detected using Western blotting with anti-HAT antibody.
D The interaction between TAP-tagged NaV1.7 and identified NaV1.7 protein–protein interactors including Scn3b, Syt2, Crmp2, Gprin1, Lat1 and Tmed10 was validated
using a co-immunoprecipitation in vitro system. The expression vectors containing cDNA of validated genes were cloned and transfected into a HEK293 cell line
stably expressing TAP-tagged NaV1.7. After transfection, TAP-tagged NaV1.7 complexes were immunoprecipitated with anti-FLAG antibody, and the selected
candidates were detected with their specific antibody using Western blotting. The results showed the expected sizes of Scn3b (32 kDa), Syt2 (44 kDa), Crmp2
(70 kDa), Gprin1 (two isoforms: 80 kDa and 110 kDa), Lat1 (57 kDa) and Tmed10 (21 kDa).
E Tissue expression pattern of TAP-tagged NaV1.7. The proteins were extracted from different tissues in both KI and WT littermate control mice and anti-FLAG used to
detect TAP-tagged NaV1.7 using Western blotting. Anti b-tubulin was used as a loading control.
F The validation of selected NaV1.7 protein interactor candidates with Nav1.7 endogenous expressing DRG tissue. First, the proteins from DRG of TAP-tagged NaV1.7
mice were extracted in 1% CHAPS lysis buffer. NaV1.7 complexes were then immunoprecipitated by anti-FLAG M2 magnetic beads. Thirteen NaV1.7 interactor
candidates including Scn3b (32 kDa), Syt2 (44 kDa), Crmp2 (70 kDa), Gprin1 (110 kDa), Lat1 (57 kDa), Tmed10 (21 kDa), Akap12 (191 kDa), Nfasc (138 kDa), Ntm
(38 kDa), Kif5b (110 kDa), Ank3 (243 kDa) and Pebp1 (23 kDa) were detected with their specific antibodies using Western blotting.
G Co-immunoprecipitation of NaV1.7 with CaV2.2. Left panel shows negative Western blot results for pull-down of transiently transfected HA-tagged CaV2.2 from TAP-
tagged NaV1.7 complex (HAT antibody for detection) in TAP-tagged NaV1.7 HEK293 stable cell line. Right panel shows control blot from whole-cell lysate of HA-tagged
CaV2.2 and TAP-tagged NaV1.7.
Source data are available online for this figure.
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Functional characterisation of Crmp2
We confirmed that Tap-tagged Nav1.7 binds directly to Crmp2,
the presumed target of the anti-epileptic and analgesic drug laco-
samide, based on binding studies (Wilson & Khanna, 2015). We
sought to evaluate the possible electrophysiological consequences
of Crmp2 binding to NaV1.7 and in addition to understand the
relevance of Crmp2 to the action of lacosamide. Transfection of
Crmp2 into a NaV1.7 stable HEK293 cell line revealed a nearly
twofold increase in sodium current density (Fig 7A–C), consistent
with Crmp2 acting directly as a transporter for NaV1.7 (Dustrude
et al, 2013). Next, we sought to investigate the effect of lacosa-
mide on sodium currents. In cells not transfected with Crmp2,
NaV1.7 currents displayed very small changes in current density
under our recording conditions following prolonged 5-h exposure
to lacosamide (Fig 7A and B). Interestingly, following 5-h incuba-
tion with lacosamide in Crmp2-transfected cells, a complete rever-
sal in the increase in NaV1.7 current density provoked by Crmp2
was observed (Fig 7A and D). This shows an interaction between
NaV1.7 and Crmp2 and demonstrates that actions of lacosamide
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Table 1. Identified NaV1.7-associated proteins (only appearing in KI group + selected candidates).
Gene symbol Protein name
UniProt
Acc







Proteins appearing in KI group only
Scn3b Sodium channel subunit beta-3 Q8BHK2 2.64E06 0.00E+00 KI only
Bola2 BolA-like protein 2 Q8BGS2 2.28E06 0.00E+00 KI only
Psma7 Proteasome subunit alpha type-7 Q9Z2U0 1.77E06 0.00E+00 KI only
Psma1 Proteasome subunit alpha type-1 Q9R1P4 1.70E06 0.00E+00 KI only
Homer2 Isoform 2 of Homer protein homolog 2 Q9QWW1-2 1.22E06 0.00E+00 KI only
Fga Isoform 2 of Fibrinogen alpha chain E9PV24-2 1.06E06 0.00E+00 KI only
Ndufv3 NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial Q8BK30 9.48E07 0.00E+00 KI only
Psma5 Proteasome subunit alpha type-5 Q9Z2U1 9.22E07 0.00E+00 KI only
Erh Enhancer of rudimentary homolog P84089 9.12E07 0.00E+00 KI only
Psmb2 Proteasome subunit beta type-2 Q9R1P3 8.92E07 0.00E+00 KI only
Rp2 Isoform 2 of Protein XRP2 Q9EPK2-2 8.67E07 0.00E+00 KI only
Pebp1 Phosphatidylethanolamine-binding protein 1 P70296 8.32E07 0.00E+00 KI only
Plekhb1 Isoform 2 of Pleckstrin homology domain-containing
family B member 1
Q9QYE9-2 8.18E07 0.00E+00 KI only
Omp Olfactory marker protein Q64288 6.62E07 0.00E+00 KI only
Ndufb10 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 Q9DCS9 6.24E07 0.00E+00 KI only
Fabp7 Fatty acid-binding protein, brain P51880 5.87E07 0.00E+00 KI only
Apoo Apolipoprotein O Q9DCZ4 5.53E07 0.00E+00 KI only
Psmb5 Proteasome subunit beta type-5 O55234 4.79E07 0.00E+00 KI only
Psmd12 26S proteasome non-ATPase regulatory subunit 12 Q9D8W5 4.47E07 0.00E+00 KI only
Mlst8 Target of rapamycin complex subunit LST8 Q9DCJ1 4.22E07 0.00E+00 KI only
Flna Filamin-A Q8BTM8 4.00E07 0.00E+00 KI only
Psma4 Proteasome subunit alpha type-4 Q9R1P0 3.79E07 0.00E+00 KI only
Oxct1 Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial Q9D0K2 3.72E07 0.00E+00 KI only
Psmb4 Proteasome subunit beta type-4 P99026 3.54E07 0.00E+00 KI only
Tusc5 Tumour suppressor candidate 5 homolog Q8C838 3.22E07 0.00E+00 KI only
Map2 Microtubule-associated protein (Fragment) G3UZJ2 2.41E07 0.00E+00 KI only
Psmd4 Isoform Rpn10B of 26S proteasome non-ATPase regulatory subunit 4 O35226-2 2.13E07 0.00E+00 KI only
Rab1A Ras-related protein Rab-1A P62821 1.90E07 0.00E+00 KI only
Calb2 Calretinin Q08331 1.83E07 0.00E+00 KI only
Actr2 Actin-related protein 2 P61161 1.34E07 0.00E+00 KI only
Akap12 Isoform 2 of A-kinase anchor protein 12 Q9WTQ5-2 1.23E07 0.00E+00 KI only
Gpx4 Isoform Cytoplasmic of Phospholipid hydroperoxide
glutathione oxidase
O70325-2 1.15E07 0.00E+00 KI only
Ahsa1 Activator of 90-kDa heat-shock protein ATPase homolog 1 Q8BK64 1.12E07 0.00E+00 KI only
Htatsf1 HIV Tat-specific factor 1 homolog Q8BGC0 9.15E08 0.00E+00 KI only
Sart3 Squamous cell carcinoma antigen recognised by T cells 3 Q9JLI8 8.80E08 0.00E+00 KI only
Wdr7 WD repeat-containing protein 7 Q920I9 8.24E08 0.00E+00 KI only
Rbm10 Isoform 3 of RNA-binding protein 10 Q99KG3-3 7.90E08 0.00E+00 KI only
Tkt Transketolase P40142 7.83E08 0.00E+00 KI only
Tmed10 Transmembrane emp24 domain-containing protein 10 Q9D1D4 7.75E08 0.00E+00 KI only
Ntm Neurotrimin Q99PJ0 7.69E08 0.00E+00 KI only
Lnp Protein lunapark Q7TQ95 7.52E08 0.00E+00 KI only
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on Nav1.7 function are predominantly mediated through Crmp2
binding.
It has been shown that the activity of N-type voltage-gated
calcium channels (CaV2.2) in relation to neurotransmitter release
from presynaptic terminals in pain pathways is regulated by its
protein interactor Crmp2 (Chi et al, 2009; Brittain et al, 2011).
Our study now demonstrates that Crmp2 is also a direct protein
interactor of Nav1.7. Therefore, we tested the possibility that
Nav1.7 is involved in neurotransmitter release linked to Cav2.2
through Crmp2 using co-IP in an in vitro system in HEK
cells. However, the results show that Cav2.2 was not immuno-
precipitated together with Nav1.7 (Fig 5G), suggesting that
CaV2.2 and NaV1.7 may regulate neurotransmitter release
independently.
We further investigated the function of NaV1.7 in relation to
presynaptic neurotransmitter release using immunohistochemistry
to identify distribution changes in neurotransmitter CGRP and
substance P (SP) in the dorsal horn of the spinal cord in NaV1.7
knockout mice (Nassar et al, 2004). However, there was no obvious
alteration of CGRP or SP levels in lamina I and II in the spinal cord
in NaV1.7 knockout mice compared to wild-type littermates
(Fig EV2). Thus, levels of neurotransmitters are unaffected by
inhibiting release in NaV1.7 null mutants.
Interactions between Nav1.7 and opioid receptor signalling
Recently a massive potentiation of opioid signalling has been
described in sensory neurons of NaV1.7 null mutant mice (Isensee
et al, 2017). This effect is specific for NaV1.7 as it is not replicated
in NaV1.8 null mutant mice. We found that Gprin1, a l-opioid
receptor-binding protein (Ge et al, 2009), is also associated with
NaV1.7 (Table 1). Furthermore, the protein interaction between
Gprin1 and NaV1.7 was confirmed with co-IP in vitro (Fig 5D).
This suggests close proximity between the sodium channel NaV1.7
and opioid receptors whose efficacy is known to be regulated by
sodium.
Table 1 (continued)
Gene symbol Protein name
UniProt
Acc







Ddb1 DNA damage-binding protein 1 Q3U1J4 7.32E08 0.00E+00 KI only
Mpp2 Isoform 2 of MAGUK p55 subfamily member 2 Q9WV34-2 6.92E08 0.00E+00 KI only
Camsap3 Isoform 2 of calmodulin-regulated spectrin-
associated protein 3
Q80VC9-2 6.56E08 0.00E+00 KI only
Ppp1r9a Protein Ppp1r9a H3BJD0 6.25E08 0.00E+00 KI only
Pccb Propionyl-CoA carboxylase beta chain, mitochondrial Q99MN9 6.16E08 0.00E+00 KI only
Des Desmin P31001 5.91E08 0.00E+00 KI only
Cdh2 Cadherin-2 P15116 5.88E08 0.00E+00 KI only
Agpat3 1-acyl-sn-glycerol-3-phosphate acyltransferase gamma Q9D517 5.50E08 0.00E+00 KI only
Ogt Isoform 2 of UDP-N-acetylglucosamine Q8CGY8-2 5.42E08 0.00E+00 KI only
Ahnak Protein Ahnak E9Q616 5.34E08 0.00E+00 KI only
Nfasc Neurofascin Q810U3 4.96E08 0.00E+00 KI only
Mccc2 Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial Q3ULD5 4.63E08 0.00E+00 KI only
Mpdz Isoform 2 of Multiple PDZ domain protein Q8VBX6-2 3.66E08 0.00E+00 KI only
Tln1 Talin-1 P26039 3.32E08 0.00E+00 KI only
Dsp Desmoplakin E9Q557 2.17E08 0.00E+00 KI only
Slc4a8 Isoform 2 of Electroneutral sodium bicarbonate exchanger 1 Q8JZR6-2 1.82E08 0.00E+00 KI only
Slc7a14 Probable cationic amino acid transporter Q8BXR1 1.07E08 0.00E+00 KI only
Sgk223 Tyrosine-protein kinase SgK223 Q571I4 7.46E09 0.00E+00 KI only
Other selected candidates for validation
Slc7a5/Lat1 Large neutral amino acids transporter small subunit 1 Q9Z127 1.66E07 3.11E08 5.34
Kif5b Kinesin-1 heavy chain Q61768 4.04E07 1.00E07 4.04
Ank3 Ankyrin-3 (Fragment) S4R2K9 3.06E07 8.73E08 3.51
Dpysl2/Crmp2 Dihydropyrimidinase-related protein 2 O08553 7.58E06 2.26E06 3.35
Gprin1 G protein-regulated inducer of neurite outgrowth 1 Q3UNH4 3.94E07 2.05E07 1.92
Syt2 Synaptotagmin-2 P46097 3.81E06 2.46E06 1.55
MGI approved gene symbols and protein names, and UniProt accession numbers are shown. Average of spectral counts from TAP-tagged Nav1.7 knock-in mice
(KI) and littermate wild-type control mice (WT) and the ratios from KI group and WT group are displayed.
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Discussion
Experimental evidence has shown that protein–protein interactions
play a key role in trafficking, distribution, modulation and stability of
ion channels (Shao et al, 2009; Catterall, 2010; Leterrier et al, 2010;
Bao, 2015; Chen-Izu et al, 2015; Laedermann et al, 2015). Here, we
mapped the protein interaction network of NaV1.7 using an AP-MS
proteomic approach with an epitope-tagged NaV1.7 knock-in mouse
line. This is the first report to define an ion channels’ macromolecular
complex using an epitope-tagged gene-targeted mouse.
AP-MS requires specific high-affinity antibodies against the target
proteins of interest (Wildburger et al, 2015). However, binding may
compete with normal protein–protein interactions. To overcome
these limitations, epitope tags on target proteins were introduced
into the AP-MS system. In the last decade, single-step and tandem
affinity purification have been widely applied in protein–protein
interaction studies (Fernandez et al, 2009; Wildburger et al, 2015).
In contrast to ss-AP, TAP produces lower background and less
contamination. However, due to its longer experimental washing
procedures and two-step purification, TAP coupled with MS analysis
may not be sufficiently sensitive to detect transient and dynamic
protein–protein interactions. In recent years, along with newly
developed highly sensitive mass spectrometer techniques and
powerful quantitative proteomics analysis methods, ss-AP was
employed to identify both transient and stable protein–protein inter-
actors (Oeffinger, 2012; Keilhauer et al, 2015). For example, using a
single-step FLAG approach, Chen and colleagues defined specific
novel interactors for the catalytic subunit of PP4, which they had
not previously observed with TAP-MS (Chen & Gingras, 2007).
Thus, ss-AP followed by sensitive LC-MS/MS analysis was applied in
this study. In fact, many dynamic modulator proteins were identified
to interact with NaV1.7 in this study, such as calmodulin (Calm1;
Table EV1), which was found to bind to the C-terminus of other
VGSCs NaV1.4 and NaV1.6, thereby regulating channel function
(Herzog et al, 2003). Apart from the sodium channel b3 subunit and
the known NaV1.7 protein interactor Crmp2, a broad range of impor-
tant novel interactors that belong to different protein classes, such as
cytoskeletal/structural/cell-adhesion proteins and vesicular/traf-
ficking/transport proteins (Fig 6B), have been identified in this study.
Four proteins, Crmp2, Nedd4-2, FGF13 and Pdzd2, have previously
been reported as NaV1.7 protein interactors (Sheets et al, 2006; Shao
et al, 2009; Ho et al, 2012; Yang et al, 2017). Laedermann et al
(2013) showed that the E3 ubiquitin ligase Nedd4-2 regulates NaV1.7
by ubiquitinylation in the pathogenesis of neuropathic pain. Shao
et al (2009) demonstrated that Pdzd2 binds to the second intracellu-
lar loop of NaV1.7 by a GST pull-down assay in an in vitro system.
Recently, Zhang’s group revealed that FGF13 regulates heat nocicep-
tion by interacting with NaV1.7 (Yang et al, 2017). We did not find
the previously reported NaV1.7 interactors Nedd4-2, FGF13 or Pdzd2.
This may be because Nedd4-2 and FGF13 only bind to NaV1.7 in
neuropathic pain conditions and in heat nociception, respectively,
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Figure 6. Analysis of NaV1.7 complex proteins.
A Cellular localisation of identified NaV1.7-interacting proteins.
B Protein class of identified NaV1.7-interacting proteins categorised using PANTHER Classification System.
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Scn3b and Crmp2 have previously been proposed to associate
with NaV1.7 (Ho et al, 2012; Dustrude et al, 2013). We demon-
strated the physical interaction between these proteins and NaV1.7
by co-IP. Furthermore, we demonstrated that transient overexpres-
sion of Crmp2 can upregulate NaV1.7 current density in stably
expressing NaV1.7 HEK293 cells and that this upregulation can be
reversed by applying lacosamide. Previous studies reported that no
change in NaV1.7 currents with Crmp2 overexpression in CAD cells
(Wang et al, 2010; Dustrude et al, 2013). This could be attributed
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Figure 7. Electrophysiological characterisation of NaV1.7 in HEK293 cells following transfection with Crmp2 and incubation with lacosamide (LCM).
A Representative raw current traces of NaV1.7 stably expressed in HEK293 cells in response to the activation pulse protocol shown. Each trace shows a different
condition: + Crmp2 transfection and + incubation with 100 lM LCM.
B IV plot of NaV1.7 current density in the absence and presence of 100 lM LCM. Compared with NaV1.7 basal currents (n = 10), LCM incubation had no significant
effect on sodium channel density (n = 12, P = 0.402).
C IV plot of NaV1.7 in HEK293 cells in the presence and absence of Crmp2 transfection. Compared to NaV1.7 basal currents, Crmp2 transfection caused a significant
increase in NaV1.7 current density (n = 16, P = 0.0041).
D IV plot showing current density of NaV1.7 following transfection of Crmp2 and incubation with 100 lM LCM. Incubation with LCM reversed the Crmp2-mediated
current increase (n = 10, P = 0.0442).
Data information: Data were analysed using one-way ANOVA with Tukey’s post hoc test. All data are mean  SEM.
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conditions. Taken together, FLAG ss-AP coupled with quantitative
MS seems to be a powerful and reliable tool for investigating protein
interactions of membrane ion channels.
Using co-IP and a co-expression in an in vitro system, we also con-
firmed the direct physical interaction between NaV1.7 and novel
protein interactors of interest including Syt2, Lat1, Tmed10 and
Gprin1. Synaptotagmin is a synaptic vesicle membrane protein that
functions as a calcium sensor for neurotransmission (Chapman, 2002).
Sampo et al (2000) showed a direct physical binding of synaptotag-
min-1 with NaV1.2 at a site, which is highly conserved across all volt-
age-gated sodium channels suggesting that the synaptotagmin family
can associate with other VGSCs. NaV1.7 found at presynaptic terminals
appears to be involved in neurotransmitter release (Weiss et al, 2011;
Black et al, 2012; Minett et al, 2012). Our results revealed the physical
interaction between Syt2 and NaV1.7. Interestingly, other synaptic
proteins also coprecipitated with Nav1.7 including SNARE complex
protein syntaxin-12 (Table EV1). These data suggest that NaV1.7 may
regulate neurotransmitter release through Syt2 and syntaxin-12 in the
peripheral and central terminals of the spinal cord.
Gabapentin was developed to treat epilepsy, but it is now used to
treat various forms of chronic pain. However, the analgesic mecha-
nisms of gabapentin are not entirely clear, but involve the inhibition
of the voltage-gated calcium channel CaV2.2 by blocking the traf-
ficking of a2d-1- and a2d-1-mediated trafficking of the CaV2.2 chan-
nel complex to reduce channel activity in DRG neurons (Hendrich
et al, 2008; Cassidy et al, 2014). As the transporter of gabapentin,
Lat1 has been identified as a NaV1.7 protein interactor, and it is
conceivable that Lat1 may also be involved in the regulation of
NaV1.7 channel function. However, future experiments are required
to determine the functional significance of the Nav1.7-Lat1 interac-
tion in this regard. As a member of the p24 family, Tmed10 was
selected due to its well-characterised properties as a protein traf-
ficking regulator. Previous studies have highlighted that Tmed10
plays an important role as a cargo receptor in the trafficking of vari-
ous membrane proteins. For example, Tmed10 has been observed
to modulate the transport and trafficking of amyloid-b precursor
protein (Vetrivel et al, 2007), endogenous glycosylphosphatidylinos-
itol (GPI)-anchored proteins CD59 and folate receptor alpha (Bon-
non et al, 2010), and several G protein-coupled receptors (GPCRs)
(Luo et al, 2011). Tmed10 was confirmed as a NaV1.7 protein inter-
actor in this study, suggesting Tmed10 may regulate NaV1.7 traf-
ficking. The underlying mechanisms need to be further investigated.
VGSCs are known to exist in macromolecular complexes
(Meadows & Isom, 2005). The b subunits are members of the
immunoglobulin (Ig) domain family of cell-adhesion molecules
(CAM). As well as sodium channel a subunits, the b subunits also
bind to a variety of cell-adhesion molecules such as neurofascin,
contactin, tenascins and NrCAMs (Srinivasan et al, 1998; Ratcliffe
et al, 2001; McEwen & Isom, 2004; Cusdin et al, 2008; Namadurai
et al, 2015). In our data set (Table EV1), the sodium channel b3
subunit and some CAMs, such as Ncam1 and neurofascin, have
been found to associate with the NaV1.7 a subunit. The crystal
structure of the human b3 subunit has been solved recently. The b3
subunit Ig-domain assembles as a trimer in the crystal asymmetric
unit (Namadurai et al, 2014). This raises the possibility that trimeric
b3 subunits binding to NaV1.7 a subunit(s) form a large complex
together with other sodium channels, as well as with CAMs and
cytoskeletal proteins in the plasma membrane.
NaV1.7 has also been linked to opioid peptide expression, and
enhanced activity of opioid receptors is found in the NaV1.7 null
mutant mouse (Minett et al, 2015). Interestingly, Gprin1, which is
known to interact with opioid receptors as well as other GPCRs, was
found to co-immunoprecipitate with NaV1.7. This suggests that
GPCR sodium channel interactions could add another level of regu-
latory activity to the expression of NaV1.7. Intriguingly, opioid
receptors are well known to be regulated by sodium (Ott et al, 1988;
Fenalti et al, 2014). Deleting Nav1.8 had no effect on l-opioid recep-
tor efficacy measured with fentanyl, whilst Nav1.7 deletion potenti-
ated opioid action substantially (preprint: Kanellopoulos et al,
2017). Thus, the proximity of Nav1.7 and l-opioid receptors medi-
ated by Gprin1 may contribute to this regulation.
More recently, Branco and colleagues reported that NaV1.7 in
hypothalamic neurons plays an important role in body weight
control (Branco et al, 2016). We found that NaV1.7 was not only
present in the arcuate nucleus but also in other regions of the brain
such as the medial amygdala, medial habenula, anterodorsal thala-
mic nucleus, laterodorsal thalamic nucleus, and in the subfornical
organ, substantia nigra reticular part and the red nucleus magnocel-
lular part of the midbrain, and in neurons of the pontine nuclei
located in the hindbrain. NaV1.7 thus has other functions in the CNS
that remain to be elucidated.
Overall, the present findings provide new insights into the inter-
actome of NaV1.7 for advancing our understanding of NaV1.7 func-
tion. Our data also show that the ss-AP-coupled LC-MS/MS is a
sensitive, reliable and high-throughput approach to identify protein–
protein interactors for membrane ion channels, using epitope-tagged
gene-targeted mice.
Materials and Methods
Generation of a TAP-tagged NaV1.7-expressing stable HEK293
cell line
A HEK293 cell line stably expressing TAP-tagged NaV1.7 was estab-
lished as previously described (Koenig et al, 2015). Briefly, a sequence
encoding a TAP-tag (peptide: SRK DHL IHN VHK EEH AHA HNK IEN
LYF QGE LPT AAD YKD HDG DYK DHD IDY KDD DDK) was inserted
immediately prior to the stop codon of NaV1.7 in the SCN9A mamma-
lian expression construct FLB (Cox et al, 2006). The TAP-tag at the
extreme C-terminus of NaV1.7 comprises a HAT domain and 3 FLAG-
tags, enabling immunodetection with either anti-HAT or anti-FLAG
antibodies. The function and expression of TAP-tagged NaV1.7 in this
HEK293 cell line were characterised with both immunocytochemistry
and electrophysiological patch clamp analysis.
Generation of NaV1.7
TAP knock-in mice
The gene targeting vector was generated using a BAC homologous
recombineering-based method (Liu et al, 2003). Four steps were
involved in this procedure (Fig EV1). Step 1, two short homology
arms (HA) HA3 and HA4 corresponding to 509-bp and 589-bp
sequences within intron 26 and after exon 27 of NaV1.7,
respectively, were amplified by PCR using a BAC bMQ277g11
(Source Bioscience, Cambridge, UK) DNA as a template, and then
inserted into a retrieval vector pTargeter (Fernandez et al, 2009; gift
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from Dr. Seth GN Grant) by subcloning. Step 2, a 9.1-kb genomic
DNA fragment (3.4 kb plus 5.8 kb) was retrieved through homol-
ogous recombineering by transforming the KpnI-linearised pTar-
geter-HA3-HA4 vector into EL250 E. coli cells containing BAC
bMQ277g11. Step 3, short homology arms HA1 and HA2 corre-
sponding to 550 bp (before stop codon of NaV1.7) and 509 bp
(starting from stop codon of NaV1.7), respectively, were amplified
by PCR, and then cloned into pneoflox vector (Fernandez et al,
2009; gift from Dr. Seth GN Grant) containing the TAP-tag, leav-
ing inbetween the TAP-tag sequence, 2 LoxP sites, PGK and EM7
promoters, the G418r gene and a SV40 polyadenylation site. Step
4, the cassette flanked by two homology arms (HA1 and HA2)
was excised by XhoI and BglII digestion and transformed into
recombination-competent EL250 cells containing the pTargeter-
HA3-HA4 plasmid. Then, the TAP tag cassette was inserted into
the pTargeter-HA3-HA4 vector by recombination in EL250 E. coli
cells. The correct recombination and insertion of the targeting
cassette were confirmed by restriction mapping and DNA
sequencing. The complete gene targeting vector containing the 50-
end homologous NaV1.7 sequence of 3.4 kb and a 3
0-end homol-
ogy arm of 5.8 kb was linearised with PmeI digestion for ES cell
electroporation. All the homology arms HA1, HA2, HA3 and HA4
were amplified with NEB Phusion PCR Kit using bMQ277g111
BAC clone DNA as a template. Primers used to create the recom-
bination arms included:









To generate TAP-tagged NaV1.7 mice, the linearised targeting
vector was transfected into 129/Sv ES cells. Cells resistant to G418
were selected by culturing for 9 days. Recombined ES cell clones
were identified using Southern blot-based screening. Three clones
that were confirmed to be correct using Southern blot were injected
into C57BL/6 blastocysts at the Transgenic Mouse Core facility of
the Institute of Child Heath (ICH). The chimeric animals were
crossed to C57BL/6, and the germline transmission was confirmed
by Southern blot. The neomycin cassette was removed by crossing
with global Cre mice. The correct removal of the neomycin cassette
and TAP-tag insertion was confirmed by Southern blot, genotyping
(PCR) and RT–PCR.
The genomic DNA was extracted from ear punches and geno-




The wild-type NaV1.7 allele and TAP-tagged NaV1.7 allele gave a
170-bp band and a 411-bp band, respectively. The TAP-tagged
NaV1.7 mRNA was confirmed by RT–PCR. Briefly, total RNA was
extracted from dorsal root ganglia with Qiagen RNEasy kit (Qiagen)
and 1.0 lg was used to synthesise cDNA using Bio-Rad iScript
cDNA synthesis kit with oligo-dT primers. The following primers
were used to detect NaV1.7 mRNA:
E25-26-F (forward)—CCGAGGCCAGGGAACAAATTCC
30UTR-R (reverse)—GCCTGCGAAGGTGACTCACTCGTG
The wild-type and TAP-tagged NaV1.7 alleles gave a 1,521-bp
band and a 1,723-bp band, respectively.
Immunocytochemistry
TAP-tagged NaV1.7-HEK293 cells and their parental HEK293 cells
were plated on poly-D-lysine coated coverslips in 24-well plates
and cultured at 37°C/5% CO2 in DMEM supplemented with 10%
foetal bovine serum (Life Technologies), 50 U/ml penicillin,
50 lg/ml streptomycin and 0.2 mg/ml G418 (only for TAP-tagged
NaV1.7-HEK293 cells); 24 h later, cells were fixed in cooled
methanol at 20°C for 10 min and then permeabilised with cooled
acetone at 20°C for 1 min. After three washes with 1× PBS, the
cells were incubated with blocking buffer containing 1× PBS, 0.3%
Triton X-100 and 10% goat serum at room temperature for
30 min. Then, the fixed cells were incubated with anti-FLAG anti-
body (1:500 in blocking buffer, F1804, Sigma) at 4°C overnight.
After 3 washes with 1× PBS, cells were incubated with secondary
antibody goat anti-mouse IgG conjugated with Alexa Fluor 488
(A11017, Invitrogen) at room temperature for 2 h. Then, coverslips
were washed 3 times in 1× PBS and cells were mounted with
VECTASHIELD HardSet Antifade Mounting Medium containing
DAPI (H-1400, Vectorlabs) and visualised using a fluorescence
microscope (Leica).
Immunohistochemistry
Following anaesthesia, mice were transcardially perfused with PBS,
followed by 1% (for brain) or 4% (for spinal cord) paraformalde-
hyde in PBS. Brains and spinal cord were dissected and incubated in
fixative for 4 h at 4°C, followed by 30% sucrose in PBS for 2 days at
4°C. Tissue was embedded in O.C.T. (Tissue-Tek) and snap-frozen
in a dry ice/2-methylbutane bath. Brain coronal and spinal cord
cross cryosections (20 lm) were collected on glass slides (Super-
frost Plus, Polyscience) and stored at 80°C until further process-
ing. For FLAG-tag immunohistochemistry in the brain, sections
were incubated in blocking solution (4% horse serum, 0.3% Triton
X-100 in PBS) for 1 h at room temperature, followed by incubation
in mouse anti-FLAG antibody (F-1804, Sigma) diluted 1:200 in
blocking solution for 2 days at 4°C. Following three washes in PBS,
bound antibody was visualised using either an Alexa 488- or 594-
conjugated goat anti-mouse secondary antibody (1:800, Invitrogen).
To facilitate the identification of brain regions and the correspond-
ing bregma levels, nuclei were counterstained with Hoechst 33342
(1:10,000, Invitrogen). Sections were mounted with DAKO fluores-
cence mounting medium. Fluorescence images were acquired on an
epifluorescence microscope (BX61 attached to a DP71 camera,
Olympus) or a confocal laser scanning microscope (LSM 780, Zeiss).
Images were assembled and minimally adjusted in brightness and
contrast using Adobe Photoshop Elements 10. Bregma levels and
brain regions were identified according to the stereotaxic coordi-
nates in “The Mouse Brain” atlas by Paxinos and Franklin (2001).
The immunohistochemistry experiments in spinal cord were
performed as described previously (Zhao et al, 2010) using the follow-
ing primary antibodies: anti-FLAG antibody (1:400; F1804, Sigma),
anti-CGRP antibody (1:100; #24112, ImmunoStar), anti-substance P
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(1:100; #20064, ImmunoStar) and biotin-conjugated isolectin B4
(1:200; L2140, Sigma).
Behavioural analysis
All behavioural tests were approved by the United Kingdom Home
Office Animals (Scientific Procedures) Act 1986. Age (6–12 weeks)-
matched KI mice (four males and three females) and littermate wild-
type (WT) controls (three males and four females) were used for
acute pain behaviour studies. The experimenters were blind to the
genetic status of test animals. The Rotarod, Hargreaves’, von Frey
and Randall–Selitto tests were performed as described (Zhao et al,
2006). We used the same set of mice to perform acute behavioural
tests. The order was Rotarod, von Frey, Hargreaves and Randall–
Selitto tests. We left one-day gap between Rotarod, von Frey and
Hargreaves test, and 3-day gap between Hargreaves test and
Randall–Selitto test. The formalin test was carried by intraplantar
injections of 20 ll of 5% formalin. Age (8–12 weeks)-matched
seven male KI mice and 10 male littermate wild-type (WT) controls
were used. The mice were observed for 45 min and the time spent
biting and licking the injected paw was monitored and counted.
Two phases were categorised, the first phase lasting 0–10 min and
the second phase 10–45 min. All data are presented as
mean  SEM.
Single-step and tandem affinity purification
In each round of sample preparation for single-step and tandem
affinity purification, DRG, olfactory bulbs, spinal cord and
hypothalamus samples were homogenised using Precellys Tissue
Homogenizer and Precellys lysis kit (Precellys ceramic kit
1.4 mm, Order no. 91-PCS-CK14, Peqlab) in 1% CHAPS lysis
buffer (30 mM Tris–HCl pH 7.5, 150 mM NaCl, 1% CHAPS, 1
complete EDTA-free protease inhibitor cocktail (Roche) in 10 ml
of CHAPS lysis buffer) and further homogenised using an insulin
syringe. The lysates were incubated shaking horizontally on ice
and clarified by centrifugation at 14,000 g for 8 min at 4°C.
Protein concentrations were measured using the Pierce BCA
Protein Assay Kit (Product no. 23225, Thermofisher), and a total
starting amount of 10 mg of protein containing supernatant was
incubated with anti-FLAG M2 Magnetic beads (M8823, Sigma).
The coupling was carried out for 2 h at 4°C using an end-over-
end shaker. Magnetic beads were collected on a DynaMAG rack
(Invitrogen) and washed three times in 1% CHAPS Buffer and 1×
AcTEV protease cleavage buffer (50 mM Tris–HCl pH 8.0,
0.5 mM EDTA, 1 mM DTT). Bead-captured NaV1.7 TAP-tag
complex was released from the beads by incubation with AcTEV
protease (#12575015, Invitrogen) at 30°C for 3 h, finalising the
single-step purification. For the tandem affinity purification,
protein eluates were collected after AcTEV cleavage and 15×
diluted in protein binding buffer (50 mM sodium phosphate,
300 mM NaCl, 10 mM imidazole, 0.01% Tween 20; pH 8.0).
AcTEV-cleaved NaV1.7 and its complex were then captured using
Ni-NTA beads (#36111, Qiagen). Ni-NTA beads were washed
three times in protein binding buffer and incubated on an end-
over-end shaker overnight at 4°C. TAP-tagged NaV1.7 protein
complexes were released from the Ni-NTA beads by boiling in 1×
SDS protein sample buffer.
Western blot
Proteins for Western blot were isolated from freshly excised dif-
ferent tissues, such as DRG, spinal cord, sciatic nerve, olfactory
bulb, cortex, hypothalamus, cerebellum, skin, lung, heart and
pancreas taken from TAP-tagged NaV1.7 mice and littermate control
mice. The protein samples were prepared the same as described in
the section of single-step and tandem affinity purification in Materi-
als and Methods. Briefly, proteins extracted from different tissues
were homogenised in 1% CHAPS lysis buffer.
The nuclear fraction and cell debris were removed by centrifuga-
tion at  20,000 g for 15 min at 4°C. Protein concentrations were
determined with Pierce BCA protein assay kit, and then samples of
40 lg were separated on SDS–PAGE gel in Bio-Rad Mini-PROTEAN
Vertical Electrophoresis Cell System and blotted to the Immobilin-P
membrane (IPVH00010, Millipore) in transfer buffer (25 mM
Tris–HCl, pH 8.3, 192 mM glycine, 0.1% SDS and 20% methanol)
for 1 h at 100 V with a Bio-Rad transfer cell system. The membrane
was blocked in blocking buffer [5% nonfat milk in PBS–Tween
buffer (0.1% Tween 20 in 1× PBS)] for 1 h at room temperature
and then incubated with primary antibody anti-FLAG (1:1,000;
Sigma, catalog #F1804) and anti-HAT (1:400; LSBio, #LS-C51508) in
blocking buffer overnight at 4°C. The membrane was washed three
times with TBS–Tween (20 mM Tris, 150 mM NaCl, 0.1% Tween
20, pH 7.5) and then incubated with secondary antibody goat
anti-mouse or goat anti-rabbit IgG-HRP (1:4,000; Jackson Immuno-
Research Laboratories) in TBS–Tween at room temperature for 2 h.
Detection was performed using a Western Lightning Chemilumines-
cence Reagent (Super Signal Western Dura, Thermo Scientific,
#34075) and exposed to BioMax film (Kodak). Other primary
antibodies used for Western blotting were ankyrin-3 (Santa Cruz,
SC-12719), neurotrimin (Santa Cruz, SC-390941), Kif5b (Santa Cruz,
SC-28538), PEBP1 (Thermo fisher, 36-0700), neurofascin (Abcam,
ab31457), neuroligin (Abcam, ab177107) and AKAP12 (Abcam,
ab49849). Concentrations were applied as suggested by the
manufacturers.
Plasmids
The following plasmids were obtained from Addgene (Cambridge,
MA): Tmed10 (TMED-BIO-HIS, #51852), Lat1 (pEMS1229,
#29115). Gprin1 plasmid was obtained from OriGene
(#RC207340). In order to perform in vitro validation of NaV1.7
interaction with synaptotagmin-2, we first cloned the human gene
for insertion into a mammalian expression plasmid. Synaptotag-
min-2 was cloned from human dorsal root ganglion neuronal
tissue. Whole mRNA was first reverse-transcribed into a cDNA
library for PCR. Following insertion into a TOPO vector, this was
then used as the template to create the synaptotagmin-2 insert,
which was then successfully cloned into a pcDNA3.1 IRES-AcGFP
plasmid using the Gibson assembly method. The collapsin
Response Mediator Protein 2 (Crmp2) gene was cloned from
human dorsal root ganglia neuron mRNA and cloned into a
pcDNA3.1 plasmid using Gibson assembly. The Scn3b mamma-
lian-expressing vector was used to investigate loss of function of
NaV1.7 (Cox et al, 2006). The HA-tagged CaV2.2 was a gift from
Prof. Annette Dolphin, and was co-expressed with the auxiliary
subunits, alpha2delta-1 and beta1b.
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Co-immunoprecipitation
Mouse tissues used in Co-IP experiments were chosen on the basis
of its known NaV1.7 expression in olfactory bulb, hypothalamus,
spinal cord (lumbar enlargement), dorsal root ganglia (all cervical,
thoracic, lumbar and sacral DRGs) and sciatic nerve (both sides).
All tissues from individual mice were either pooled or treated as
individual tissue samples depending on experimental requirements.
Tissues were flash-frozen in dry ice immediately following dissec-
tion and stored at 80°C to avoid protein degradation. HEK293 cells
stably expressing TAP-tagged NaV1.7 were harvested by trypsinisa-
tion followed by centrifugation at 800 rpm for 5 min. Cell pellets
were stored at 80°C to avoid protein degradation. Samples were
lysed in a 1% CHAPS lysis buffer containing a protease inhibitor
cocktail and homogenised using ceramic zirconium oxide mix beads
of 1.4 and 2.8 mm lysing kit and homogeniser (Precellys). A total of
10–25 mg of protein was incubated with anti-FLAG M2 magnetic
beads for 2 h at 4°C. The bead–protein complex was then washed
with three cycles of five resin volumes of 1% CHAPS buffer and
once with TEV–protease buffer (Invitrogen). The tagged protein was
cleaved from the beads by the addition of TEV protease enzyme
(Invitrogen) and incubated for 3 h at 37°C to elute the protein
complex. Sample eluate was then separated from the beads and
stored at 80°C until used for either Western blotting or mass spec-
trometry. Co-immunoprecipitation in HEK293 cells was performed
after transfection of the construct with the gene of interest into the
TAP-tagged NaV1.7 stable cell line using a standard lipofectamine
protocol (Lipofectamine 200, Invitrogen, #52887). All cells were left
48 h after transfection before use in experiments.
Liquid chromatography–tandem mass spectrometry analysis
Proteins cleaved from anti-FLAG M2 magnetic beads after affinity
purification were tryptic-digested following a FASP protocol
(Wisniewski et al, 2009). In brief, proteins were loaded to 30-kDa
filters (Millipore) and then filter units were centrifuged at 14,000 g
for 15 min to remove other detergents. Two hundred ll of urea
buffer (10 mM dithiothreitol 8 M urea (Sigma) in 0.1 M Tris–HCl,
pH 8.5) was added to the filters and left at room temperature for 1 h
to reduce proteins. Then, filters were centrifuged to remove dithio-
threitol. Two hundred ll of 50 mM iodoacetamide (IAA) in urea
buffer was added to filters and left for 30 min in the dark. Filters
were centrifuged as before to remove IAA. Then, the samples were
buffer exchanged twice using 200 ll of urea buffer, and one more
time using 200 ll of 50 mM NH4HCO3 in water. Forty ll of 50 ng/ll
trypsin in 50 mM NH4HCO3 was added to filter, filters were
vortexed briefly, and proteins were digested at 37°C for overnight.
After tryptic digestion, the filters were transferred to new collection
tubes and the peptides collected by placing the filter upside down
and spinning. The samples were acidified with CF3COOH and
desalted with C18 cartridge (Waters). The pure peptides were dried
by Speedvac (Millipore) and resuspended with 20 ll of 2% ACN,
0.1% FA. Five ll of samples was injected into Orbitrap Velos mass
spectrometry (Thermo) coupled to a UPLC (Waters; The´ze´nas et al,
2013).
Analysis was carried out by nano-ultra-performance liquid chro-
matography–tandem MS (nano-UPLC-MS/MS) using a 75 lm inner
diameter × 25 cm C18 nanoAcquity UPLCTM column (1.7 lm
particle size, Waters) with a 180-min gradient of 3–40% solvent B
(solvent A: 99.9% H2O, 0.1% formic acid; solvent B: 99.9% ACN,
0.1% formic acid). The Waters nanoAcquity UPLC system (final
flow rate, 250 nl/min) was coupled to a LTQ Orbitrap Velos
(Thermo Scientific, USA) run in positive ion mode. The MS survey
scan was performed in the FT cell recoding a window between 300
and 2,000 m/z. The resolution was set to 30,000. Maximum of 20
MS/MS scans were triggered per MS scan. The lock mass option
was enabled, and polysiloxane (m/z 371.10124) was used for inter-
nal recalibration of the mass spectra. CID was done with a target
value of 30,000 in the linear ion trap. The samples were measured
with the MS setting charge state rejection enabled, and only more
than 1 charges procures ions selected for fragmentation. All raw MS
data were processed to generate MGF files (200 most intense peaks)
using the Proteowizard v.2.1.2476 software. The identification of
proteins was performed using MGF files with the central proteomics
facilities pipeline. Mus musculus (Mouse) database containing
entries from UniProtKB was used in CPF Proteomics pipeline for
data analysis. This pipeline combines database search results from
three search engines (Mascot, OMSSA and X!tandem k-score). The
search was carried out using the following parameters. Trypsin was
the enzyme used for the digestion of the proteins, and only one
missed cleavage was allowed. The accepted tolerance for the precur-
sor was 20 ppm and 0.5 Da for the fragment. The search encom-
passed 1+, 2+ and 3+ charge state, fixed modification for cysteine
carbamidomethyl and variable modification for asparagine and
glutamine deamidation, and methionine oxidation. All trypsin frag-
ments were added to an exclusion list. False discovery rate was
calculated by peptide/proteinprophet or estimated empirically from
decoy hits a 1% FDR cut-off was used to filter identified proteins.
The label-free analysis was carried out using the normalised spectral
index (SINQ; Trudgian et al, 2011). The mass spectrometry proteo-
mics data have been deposited to the ProteomeXchange Consortium
(http://www.proteomexchange.org/) via the PRIDE (Vizcaı´no et al,
2016) partner repository with the dataset identifier PXD004926.
Electrophysiology and patch clamp recordings
Whole-cell patch clamp recordings were conducted at room
temperature (21°C) using an AxoPatch 200B amplifier and a Digi-
data 1322A digitiser (Axon Instruments), controlled by Clampex
software (version 10, Molecular Devices). Filamented borosilicate
microelectrodes (GC150TF-10, Harvard Apparatus) were pulled on
a Model P-97 Flaming/Brown micropipette puller (Sutter Instru-
ments) and fire-polished to a resistance of between 2.5 and
4 MOhm. Standard pipette intracellular solution contained: 10 mM
NaCl, 140 mM CsF, 1.1 mM EGTA, 1 mM MgCl2 and 10 mM
HEPES. The standard bathing extracellular solution contained:
140 mM NaCl, 1 mM MgCl2, 3 mM KCl, 1 mM CaCl2 and 10 mM
HEPES. Both intracellular and extracellular solutions were adjusted
to a physiological pH of 7.3. The amplifier’s offset potential was
zeroed when the electrode was placed in the solution. After a giga-
seal was obtained, short suction was used to establish whole-cell
recording configuration. Errors in series resistance were compen-
sated by 70–75%. Cells were briefly washed with extracellular
solution before a final 2 ml of solution was transferred to the dish.
Cells were held at 100 mV for 2 min before experimental proto-
cols were initiated. Currents were elicited by 50-ms depolarisation
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steps from 80 mV to +80 mV in 5 mV increments. Compounds
were added and mixed at the desired concentrations in extracellu-
lar solution before being added to the bath. Following addition of
the compound, protocols were repeated on previously unrecorded
cells. All currents were leak-subtracted using a p/4 protocol. The
following compounds were used in electrophysiology experiments:
lacosamide ((R)-2-acetamido-N-benzyl-3-methoxypropionamide)
was obtained from Toronto Research Chemicals Inc (L098500) and
tetrodotoxin was obtained from Sigma-Aldrich (T8024). Incubation
with lacosamide was done for 5 h prior to recording.
Voltage-clamp experiments were analysed using pCLAMP soft-
ware and Origin (OriginLab Corp., Northampton, MA) software
programs. Current density–voltage analysis was carried out by
measuring peak currents at different applied voltage steps and
normalised to cell capacitance (pA/pF). Voltage-dependent activa-
tion data were fitted to a Boltzmann equation y = (A2 + (A1  A2)/
(1 + exp((Vh  x)/k)))*(x  Vrev), where A1 is the maximal
amplitude, Vh is the potential of half-maximal activation, x is the
clamped membrane potential, Vrev is the reversal potential and k is
a constant. All Boltzmann equations were fitted using ORIGIN
software.
NaV1.7 interaction protein selection and function analysis
Candidate proteins that may interact with Nav1.7 were selected
by two criteria: (i) present in at least two knock-in biological
experiments but absent from wild-type experiments; (ii) present
in more than three knock-in and more than one wild-type experi-
ments, the ratio of average abundance is more than 1.5-fold
increased in knock-in experiments as compared with wild-type
experiments. Further cellular component and function classifi-
cation were performed on PANTHER Classification System (11.0).
Ingenuity pathway analysis (IPA) (QIAGEN) was used to elucidate
pathways and protein interaction networks using candidate
proteins.
Southern blot analysis
The genomic DNA was extracted from either ES cells or tails of mice
following the procedures as described (Sambrook & Russell, 2001).
The probes for Southern blot were amplified by PCR using mouse
genomic DNA isolated from C57BL/6 as a template and purified
with a Qiagen Gel Purification Kit. The restriction enzymes StuI,
BspHI and PsiI were used to digest genomic DNA for either wild-
type and knock-in bands. The sizes of wild-type and knock-in bands
are shown in Fig 2B. The primers used to create probes (50 external
probe: 768 bp; 30 external probe: 629 bp) included:
50PF (50 probe, forward)—ACCAAGCTTTTGATATCACCATCAT
50PR (50 probe, reverse)—CAACTCGAGAACAGGTAAGACATGA
CAGTG
30PF (30 probe, forward)—TTTAAGCTTCCTGCCCCTATTCCTGCT
30PR (50 probe, reverse)—TTAGGATCCATGCACTACTGACTTGCT
TATAGGT
Statistical analysis
Statistical analysis was performed using either repeated-measures
ANOVA with Bonferroni post hoc testing or unpaired Student’s t-test
as described in the results or figure legends. The GraphPad Prism
6.0 was used to perform the statistical analysis. All data are
presented as mean  SEM, and significance was determined at
P < 0.05.
Expanded View for this article is available online.
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